Traders should monitor near-term revenue recognition from the U.S. and Canadian contracts, particularly the $35M+ CAD expected in 2026. The recurring nature of international orders suggests potential for further demand, supporting valuation upside in a low-market-cap biodefense play.
Price Chart
Executive Summary
Emergent BioSolutions announced a $54 million contract extension with the U.S. government for VIGIV, a treatment for smallpox vaccine complications, and $6.6 million in new international orders for its ACAM2000 smallpox vaccine. These contracts reinforce the company's role in global biodefense preparedness and follow recent agreements with Canada worth up to $140 million CAD.
Key Financial Metrics
Key Facts
- Secured $54 million USD U.S. government contract (ASPR) for CNJ-016® (VIGIV) under an existing 10-year agreement
- Received $6.6 million USD in new international orders for ACAM2000® smallpox vaccine from a recurring customer
- Recent multi-year agreements with Government of Canada valued up to $140 million CAD, with over $35 million CAD expected in 2026
- Contracts support national and global biodefense strategies amid rising biological threat concerns
Financial Impact
$60.6 million in new or incremental contract awards (including $54M U.S. and $6.6M international); over $35M CAD (~$25.5M USD) expected revenue in 2026 from Canada
Risk Factors
- Revenue recognition timing may be back-end loaded or dependent on delivery milestones
- Forward-looking statements subject to execution risk and government procurement delays
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262595 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | Press Release | $4.45 $5.68 | ▼ −27.64% | ▼ −28.70% | $6.29 (−41.35%) |
Jun 29, 2026 13w ago | 8-K | $8.46 $7.26 | ▼ −14.18% | ▼ −13.90% | $6.29 (−25.65%) |
Jun 4, 2026 17w ago | Press Release | $8.44 $8.28 | ▼ −1.90% | ▼ −0.52% | $6.29 (−25.47%) |
Apr 30, 2026 22w ago | Press Release | $8.47 $8.49 | ▲ +0.24% | ▼ −5.05% | $6.29 (−25.74%) |
Apr 30, 2026 22w ago | Insider Cluster | $8.23 $9.18 | ▲ +11.54% | ▲ +6.58% | $6.29 (−23.57%) |
Apr 29, 2026 22w ago | Press Release | $7.99 $9.18 | ▲ +14.89% | ▲ +8.85% | $6.29 (−21.28%) |
Apr 29, 2026 22w ago | Press Release | $7.99 $9.18 | ▲ +14.89% | ▲ +8.85% | $6.29 (−21.28%) |
Apr 28, 2026 22w ago | DEFA14A | $8.23 $9.13 | ▲ +10.94% | ▲ +5.47% | $6.29 (−23.57%) |
Apr 28, 2026 22w ago | Press Release | $8.23 $9.13 | ▲ +10.94% | ▲ +5.47% | $6.29 (−23.57%) |
Apr 27, 2026 22w ago | DEFA14A | $8.23 $9.13 | ▲ +10.94% | ▲ +5.47% | $6.29 (−23.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access